Market Signal Briefing

Original U.Today article

Sat, 27/12/2025 - 18:59

Can the rate of Ethereum (ETH) return above the $3,000 mark by the end of the week?

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Most of the coins are in the green zone again, according to CoinStats.

 ETH chart by CoinStatsETH/USDThe rate of Ethereum (ETH) has risen by 0.63% over the last day.

Image by TradingViewOn the hourly chart, the price of ETH is in the middle of the local channel between the support of $2,921 and the resistance of $2,938. As neither side is dominating, there are low chances to see sharp moves by tomorrow.

Image by TradingViewOn the bigger time frame, the situation is similar. The technical position of ETH has not changed a lot since yesterday.

You Might Also Like

The volume is low, confirming the absence of buyers' and sellers' energy. All in all, sideways trading around the current prices is the more likely scenario until the end of the week.

Image by TradingViewFrom the midterm point of view, the rate of the main altcoin does not have enough strength for a sharp move. In this case, traders are unlikely to witness sharp ups or downs soon.

Ethereum is trading at $2,928 at press time.

Related articles

BitMEX co-founder Arthur Hayes is in the news today after he accelerated accumulation across LDO and PENDLE within a tight window. In fact, he committed roughly $1.03M into LDO and about $973K into PENDLE. 

Here, the timing stands out. Especially since both assets seemed to be trading near compressed structures after extended downtrends on the charts. 

Rather than spreading capital broadly, Hayes’s focus is on two DeFi primitives tied to staking and yield. Such a concentration matters. 

These buys arrived before confirmed trend reversals, not after breakouts. Therefore, the activity could be a sign of positioning ahead of expected movement. 

When large capital enters during structural compression, it often alludes to preparation rather than reaction.

PENDLE derivatives activity starts warming up
PENDLE’s derivatives metrics confirmed growing participation at press time. Trading volume surged by 29% to $78.9M, while Open Interest expanded by 7% to $43.09M. Such a combination usually signals fresh leverage entering the market, not traders closing positions. 

The price reacted constructively to the same, pushing higher instead of stalling. Importantly, leverage growth remained controlled, reducing liquidation risks. 

Therefore, speculative interest appeared to rebuild gradually rather than aggressively. Such an environment ordinarily favors continuation attempts. 

When Open Interest rises alongside the price and volume, markets often transition from compression to expansion. 

Hayes’s PENDLE entry seemed to align with this shift, reinforcing the idea of early positioning rather than late momentum chasing.

LDO traders lean long, but stay measured
LDO positioning data lent more confirmation. Binance long accounts climbed towards 60%, pushing the long-short ratio close to 1.5. 

Bulls now hold a clear edge. And yet, shorts remain active too. Overcrowded longs often precede reversals, but LDO has not reached that stage yet. 

The price has also continued to grind higher, rather than spike vertically. Such behavior often reflects controlled optimism. 

However, broader market caution still lingers. Therefore, LDO’s long bias could be a sign of early confidence, not exhaustion. When rising long exposure aligns with large spot accumulation, probability favors continuation rather than renewed downside.

PENDLE structure confirms early reversal attempt
On the price charts, PENDLE broke above its descending channel after defending the $1.67 demand zone – A level that halted downside pressure multiple times. 

At press time, it was trading near $1.88, reclaiming the channel midpoint and shifting short-term structure bullish. 

This move did not occur in isolation though. Open Interest rose by 5% to $43.09M, while derivatives volume surged by 29% to $78.9M – Confirming active participation during the breakout. 

Momentum also seemed to support continuation. The MACD histogram flipped positive, with Signal Lines turning north and indicating a hike in upside momentum. 

Holding above $1.95 will keep the reversal intact, while rejection risks a pullback towards $1.67 – A level that now acts as key invalidation.

Source: TradingView

LDO wedge break signals stabilization
On the other hand, LDO has pushed out of a prolonged descending wedge after repeatedly holding the $0.55–$0.56 support band – A zone that absorbed selling pressure throughout December. 

The altcoin was valued at $0.57 at press time, stabilizing above the wedge breakout level. Momentum conditions have improved meaningfully too. In fact, the MACD histogram turned positive, while the Signal lines converged and hinted at a bullish crossover. 

Positioning data seemed to support this shift too, with long accounts rising towards 59–60%, yet without excessive crowding. 

Structurally, the next resistance lies at $0.67, where the prior breakdown occurred, followed by a higher target near $0.88. 

A breakout above $0.67 would confirm trend continuation, while a loss of $0.56 would invalidate the breakout and reopen downside risk.

Source: TradingView

Are LDO and PENDLE being positioned for a DeFi rally?
Hayes’s clustered accumulation, rising Open Interest in PENDLE, strengthening long bias in LDO, and confirmed technical breakouts all align clearly. The positioning remains early, not crowded. Therefore, risk might be skewed towards continuation rather than rejection. 

If PENDLE holds above $1.95 and LDO reclaims $0.67, both assets could head towards higher resistance zones. 

This could be indicative of strategic preparation for a DeFi-led move, one driven by structure and participation rather than speculation alone.

Final Thoughts

LDO and PENDLE exhibited aligned structural strength backed by positioning and participation.
Hayes’s accumulation might be anticipatory, favoring continuation rather than reactive buying. 

TLDR: 

Institutions deploy fresh capital each January while traditional assets trade at highs and crypto remains below peaks.
Tax-loss harvesting creates December selling that reverses in January as investors re-enter identical positions.
Bitcoin’s 50-week EMA sits near $98,200, with historical patterns suggesting potential rally to $100,000-$102,000 range.
A 20% Bitcoin move historically produces 35-40% gains in large-cap altcoins and 60-80% moves in smaller tokens.

Q1 2026 may bring positive momentum for Bitcoin and altcoins based on historical patterns and market dynamics. 

Crypto analyst Crypto Rover outlined three factors that could drive prices higher in early 2026. These factors include fresh capital deployment, year-end tax strategies, and Bitcoin’s cyclical patterns. 

The analysis comes as traditional assets trade near all-time highs while many digital assets remain below their peaks. Institutions may view this gap as an opportunity for capital allocation.

Institutional Capital Flow and Market Positioning
Crypto Rover noted on X that hedge funds and asset managers typically deploy fresh capital at the start of each year. 

This pattern occurs consistently across the financial sector. January traditionally sees new money entering markets as institutions execute their annual strategies. Currently, gold trades near record levels while silver and major stock indices also sit at elevated prices.

🚨 Q1 2026 COULD BE BULLISH FOR BTC AND ALTS.

Here's why:

1) Fresh capital gets deployed at the start of the year

Every January, hedge funds, asset managers, and institutions put new money to work.

That happens every single year.

Right now, most traditional assets already… pic.twitter.com/j9VfVcxG8c

— Crypto Rover (@cryptorover) December 27, 2025

Bitcoin and numerous altcoins remain below their all-time highs despite recent market activity. This price differential matters to institutional investors seeking value. 

When liquidity expands in financial markets, capital flows toward assets that appear less overvalued. Crypto markets remain relatively small compared to traditional finance. Therefore, even modest reallocation from large funds can create substantial price movements in digital assets.

The analyst emphasized that crypto fits the profile institutions seek during capital deployment cycles. 

Traditional assets already appear crowded at current valuations. Meanwhile, digital assets offer exposure to growth potential without chasing extended rallies. This dynamic has previously led to strong first-quarter performance in cryptocurrency markets.

Tax Harvesting Effects and Cyclical Technical Patterns
December selling pressure often stems from tax-loss harvesting rather than bearish sentiment. Investors sell losing positions before year-end to realize tax benefits. 

Many participants then re-enter identical positions in January. This creates a predictable shift in market dynamics. Selling pressure evaporates while buying demand returns simultaneously. The transition has historically fueled positive price action in early quarters.

Bitcoin follows a four-year market cycle that has shown consistent patterns. The previous cycle saw Bitcoin decline from $69,000 to $32,000 before rallying. 

The recovery brought prices to approximately $48,000 as Bitcoin reclaimed its 50-week exponential moving average. 

Today, that same technical level sits near $98,200. A repeat of this pattern in Q1 2026 could push Bitcoin toward $100,000 to $102,000, representing an 18% gain from current levels.

Altcoins typically amplify Bitcoin’s movements during bullish phases. Historical data shows that a 20% Bitcoin rally often produces 35-40% gains in Ethereum and large-cap altcoins. 

Smaller altcoins can experience 60-80% increases before momentum fades. However, Crypto Rover cautioned that such moves may represent relief rallies rather than sustained bull markets. 

The pattern could create temporary optimism before markets potentially resume downward trends.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The market is mainly rising on the first day of the weekend, according to CoinStats.

Top coins by CoinStatsBTC/USDThe price of Bitcoin (BTC) has risen by 0.68% over the last 24 hours.

Image by TradingViewOn the hourly chart, the rate of BTC has set a local resistance at $87,702. However, if the daily bar closes near that mark, traders may see further growth to the $88,000 zone shortly.

Image by TradingViewOn the bigger time frame, neither side has accumulated enough energy to seize the initiative.

You Might Also Like

In this case, consolidation in the narrow range of $87,000-$89,000 is the more likely scenario.

Image by TradingViewFrom the midterm point of view, the picture is similar. The price of the main crypto is in the middle of the channel, which means traders are unlikely to see increased volatility until the end of the month.

Bitcoin is trading at $87,532 at press time.

Rivian stock performed very well in 2025. Next year could bring more gains.

Shares of Rivian Automotive (RIVN 1.16%) languished for most of 2025. From Jan. 1 to Nov. 1, the company's stock price barely budged, although there were sporadic ups and downs along the way. Over the past month or so, however, shares have skyrocketed in value by more than 40%.

I have been urging investors to take a closer look at Rivian stock all year. In many ways, the company appears to have the potential to become the next Tesla. Even after the latest price spike, shares still appear to be a long-term buy for several reasons, the most significant of which is expected to see serious progress in 2026.

Investors finally realize Rivian is an AI stock
Take a quick look at Tesla's valuation and you'll realize that its stock is priced at a huge premium to nearly every other electric vehicle (EV) stock. It trades at a price-to-sales ratio of around 17. Rivian, meanwhile, trades at just 4.2 times sales.

There are many reasons for Tesla's premium. The company has a huge capital advantage, plus the best brand recognition in the industry. But it also has a leading position in robotaxis, a market that some experts believe will eventually be worth more than $5 trillion.

Today's Change

(

-1.16

%) $

-0.24

Current Price

$

20.89

The robotaxi market looks like a high-tech business. But it's much more than that. Investors have been betting on autonomous-driving stocks for more than a decade.

Progress has been slow. Cameras and detection devices cost a lot of money, and real-world testing has been limited due to safety and regulatory concerns. But artificial intelligence (AI) has vastly accelerated the timeline in recent years.

"There is a massive leap in AI happening right now, and it is resulting in smarter end-to-end AI systems that can learn much more efficiently, are interpretable, and can generalize to every possible scenario on the road," said Raquel Urtasun, the CEO of Waabi, a company that specializes in self-driving technology. "These advances result in autonomous vehicles with superhuman capabilities that will enhance road safety and transform transportation as we know it."

Tesla has wisely invested heavily in AI, and investors have been keen to reward it for its efforts. In general, AI stocks have performed very well in 2025, so being lumped into that category has created direct gains for shareholders.

For most of the year, Rivian was not considered an AI stock. But I repeatedly pointed out how Rivian was also investing heavily into AI, just like Tesla. Rivian scheduled an AI day in early December, and shares seemingly started rising based on expectations.

Executives largely delivered, with fresh updates on hands-free highway assist, point-to-point navigation, eyes-off alerts, and personal level 4 autonomy. Expect the EV maker's AI progress to continue to strengthen in 2026. But there's a catalyst I'm even more excited about over the near term.

A Rivian pickup outside company headquarters. Source: Rivian

Rivian will finally compete with Tesla next quarter
Tesla has many vehicle models on the market. But its cheapest two models -- the Model Y and Model 3 -- account for more than 90% of its vehicle sales. To compete directly with Tesla, EV makers must have several impressive models priced under $50,000.

Thus far, few companies have achieved this feat. Most competing EVs are either too expensive or are priced cheaply with lackluster features and relatively minimal range.

Rivian currently has only two models on the road: the R1S and R1T. Both are priced above $70,000, significantly above what most consumers are willing to pay. But next quarter, production is expected to begin on the R2, its first model priced under $50,000. Two more models will follow: the R3 and R3X, both expected to be priced under $50,000.

Within a few months, Rivian could go from being a niche luxury automaker with AI upside to a legitimate Tesla competitor. More vehicles on the road give it more real-world data, further strengthening its AI.

Even after the recent share price run-up, Rivian still has a market cap of less than $30 billion. Compare that to Tesla's $1.5 trillion valuation, and the long-term upside in Rivian stock becomes clear.

Teladoc's collapse has been dramatic. But are shares cheap enough to make them a buy?

There was a time when Teladoc Health (TDOC 1.79%) was a high-flying market darling. Helped by its positioning as an early mover in telehealth and a surge in online visits due to the COVID-19 pandemic, shares soared to euphoric levels. Unfortunately, today the stock faces the exact opposite sentiment. Parts of the company's business continue to struggle, and investors have punished the stock. In fact, the stock sits about 98% below its February 2021 high.

On the latest earnings call, CEO Charles Divita described 2025 as a "repositioning year" as the company pushes product changes and tries to improve its value proposition. Part of this effort will include addressing significant weaknesses in its online therapy business, BetterHelp.

But has the stock fallen too far? Unfortunately, the company's current challenges may still outweigh its stock price.

Image source: Getty Images.

BetterHelp is dragging on results
Teladoc's revenue declined 2% year over year in the third quarter of 2025, landing at about $626 million.

Segment performance puts this decline into context. Third-quarter integrated care revenue (Teladoc's virtual healthcare business) rose 2% year over year to about $390 million. But BetterHelp revenue fell 8% to approximately $237 million.

Looking beyond integrated care's revenue trends to its underlying membership metrics reveals some promising trends in the segment. Teladoc's U.S. integrated care membership ended the third quarter at 102.5 million, up 9% year over year. And its chronic care program, which also falls into Teladoc's integrated care segment, saw enrollment reach 1.17 million -- down 1% year over year but up more than 4% sequentially.

But Teladoc still needs BetterHelp to cooperate. Management is trying to move the service toward insurance acceptance as opposed to its previous emphasis on cash-paying customers.

Management indicated that it is seeing signs of this repositioning of BetterHelp starting to pay off.

Key metrics for its BetterHelp business, including conversion rates, number of sessions, and user growth, are all "trending in line with what we were expecting," said Teladoc chief financial officer Mala Murthy in the company's third-quarter earnings call.

But Murthy also noted that its U.S. direct-to-consumer cash-pay business "continues to be challenged" -- particularly from heavy competition by other players in the space who have strong offerings through insurance. But this helps validate Teladoc's pivot, Murthy explained.

That pivot may help over time. But the near-term drag is clear. BetterHelp's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin was just 1.6% in the third quarter, and average paying users fell 4% year over year to 382,000.

Today's Change

(

-1.79

%) $

-0.13

Current Price

$

7.12

A low stock price doesn't automatically make shares a buy
With the stock trading at around $7, Teladoc trades at 0.5 times sales as of this writing. On the surface, that might initially seem attractive -- especially for a company that still generates meaningful cash flow.

Teladoc reported $67.9 million of free cash flow in the third quarter. Additionally, the company also ended the quarter with $726 million in cash and cash equivalents. Looking ahead, management guided for full-year 2025 free cash flow of $170 million to $185 million.

Yet the income statement is still struggling. Teladoc posted a third-quarter net loss of $49.5 million. To be fair, the quarter included a $12.6 million non-cash goodwill impairment charge tied to its integrated care segment. Still, even if you were to add this one-time item back in, the adjusted loss remains worse than the company's net loss of $33.3 million in the year-ago quarter.

Guidance also looks weak. The company forecast fourth-quarter revenue to be between $622 million and 652 million. This compares to revenue of about $640 million in the fourth quarter of 2024 and $661 million in the fourth quarter of 2023. Further, the company expects to report a net loss per share in Q4 of $0.25 to $0.10.

Strong free cash flow or not, this business is still struggling to find a sustainable model to create shareholder value. For this reason, I'm going to personally stay on the sidelines for now.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

These businesses are innovators in their respective industries.

Investing in growth stocks can allow you as a long-term investor to participate in cutting-edge industries driving economic change ranging from healthcare to tech and beyond. Quality growth stocks can deliver consistently high returns through the years, although they tend to be more volatile and reactionary to macro shifts than many value-oriented businesses.

If you have the risk tolerance to put cash to work into these types of businesses, the returns of successful growth stocks tend to be higher than the rate of inflation, which can help preserve and increase the real purchasing power of an investor's savings over decades. Well-run growth companies often possess a sustainable competitive advantage that allows them to outperform competitors and maintain their growth trajectory.

If you have cash to put into growth stocks right now, here are two companies to consider the next time you go stock shopping.

Image source: Getty Images.

1. Intuitive Surgical
Intuitive Surgical (ISRG +0.11%) essentially created and dominates the multi-billion dollar surgical robotics market with its da Vinci systems. Once hospitals invest in these expensive systems, they are locked into purchasing high-margin recurring instruments, accessories, and services from the company. This has created an incredible source of recurring revenue that accounts for about 85% of Intuitive Surgical's overall revenue.

The company boasts a fortress-like balance sheet with significant cash reserves ($8.4 billion in cash at the end of Q3 2025) and low leverage so it can invest heavily in growth and weather economic downturns without relying on debt. It also consistently delivers strong cash flow, and is regularly profitable.

The core business continues to expand, with consistent double-digit growth in procedure volumes (up 20% in Q3 2025) and revenue (up 23% in Q3). The global robotic surgery market itself is expected to grow at a CAGR (compound annual growth rate) of over 14% through 2030, so there are generous long-term tailwinds for Intuitive Surgical to benefit from.

Today's Change

(

0.11

%) $

0.66

Current Price

$

577.81

Intuitive maintains its competitive edge through constant innovation. The launch of the next-generation da Vinci 5 system, which features advanced AI capabilities, enhanced 3D vision, and force feedback technology, is a key driver of growth. The company installed 240 of these systems in Q3 alone, compared to 110 the previous year. Additionally, during the quarter, the company's installed base of da Vinci surgical systems increased 13% year over year to 10,763 systems.

Robotic surgery is a well-established and rapidly growing technology, particularly in urology, gynecology, and gastrointestinal surgery, offering enhanced precision and improved outcomes for many complex surgical tasks. The technology is still evolving, particularly as the pace of AI (artificial intelligence) integration continues to expand. There's a tremendous growth runway for Intuitive Surgical in the lucrative surgical robotics industry, and investors could benefit from that long-term trajectory.

2. TransMedics Group
TransMedics Group (TMDX 2.49%) is known for its Organ Care System or OCS, the only FDA-approved, portable platform for warm perfusion and assessment of donor hearts, lungs, and livers. Warm perfusion is a transplant technology that keeps donor organs (such as livers, hearts, and lungs) functioning outside the body at body temperature using a machine that pumps warm, oxygenated, and nutrient-rich blood. This technology allows surgeons to assess the organ's real-time viability, repair it, and even use organs previously considered too marginal for transplant, which subsequently improves donor pool utilization and outcomes.

Its proprietary National OCS Program provides a full end-to-end organ retrieval and delivery service including its owned aviation fleet. This integrated approach streamlines logistics, improves surgical outcomes, and creates a significant competitive advantage as well as potential pricing power that TransMedics can leverage in a growing addressable market. TransMedics has demonstrated impressive financial growth recently, with total revenue for Q3 2025 reaching $143.8 million, a 32% year-over-year increase. The company has also consistently beaten analyst EPS estimates in recent quarters, and its earnings came in at $24.3 million for Q3, a 478% increase from a year ago.

Today's Change

(

-2.49

%) $

-3.16

Current Price

$

123.83

TransMedics Group is advancing several strategic initiatives to expand its OCS pipeline and international presence. In August 2025, the FDA granted conditional Investigational Device Exemption approval for the OCS Enhance Heart trial. This is a critical FDA permission that allows the testing of a new medical device (the OCS Heart System) in a clinical trial. The two-part study aims to demonstrate the superiority of TransMedics' next-generation OCS Heart perfusion over standard cold storage and is expected to be the world's largest heart preservation trial with over 650 patients.

TransMedics received similar conditional approval to initiate its Denovo Lung trial for the TransMedics OCS Lung System. Both the heart and lung trials were scheduled to begin in the fourth quarter of 2025.

The company is also developing a kidney perfusion device and plans to initiate clinical trials by late 2026 or early 2027. A full commercial launch for the OCS kidney system is targeted for 2029. In September 2025, TransMedics announced a collaboration with Mercedes-Benz Group AG to launch Italy's first dedicated ground transportation network for organ transplantation. The network will utilize a specialized fleet of Mercedes-Benz V-Class vehicles across four hubs -- Milan, Rome, Padua, and Bari -- to provide 24/7 clinical and logistical support using the OCS lung, heart, and liver systems to increase organ utilization across Italy.

The success of TransMedics' next-generation systems and its international expansion will be key to its future growth story. Long-term investors who believe in that value proposition may want to capitalize on the business's momentum by taking a position.

Discover why Archer Aviation's newest catalysts could ignite one of the biggest breakout moments in the eVTOL market.

Archer Aviation (ACHR 2.95%) is entering a pivotal moment as new military technology partnerships and progress toward FAA certification position the company for potential explosive growth. With commercial testing underway in the UAE and strong investor interest, Archer could become a leading force in next-generation electric flight.

Stock prices used were the market prices of Dec. 19, 2025. The video was published on Dec. 25, 2025.

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

CFO Ann Thornton disposed of 4,080 directly held shares on Dec. 19, 2025, generating a transaction value of $334,356 at a weighted average sale price of $81.95 per share. This sale represented 12.36% of her direct holdings, reducing her stake from 33,015 to 28,935 shares.

NEW YORK, Dec. 27, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Coupang, Inc. (NYSE: CPNG) between August 6, 2025 and December 16, 2025, both dates inclusive (the “Class Period”), of the important February 17, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Coupang securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Coupang class action, go to https://rosenlegal.com/submit-form/?case_id=8383 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 17, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Coupang had inadequate cybersecurity protocols that allowed a former employee to access sensitive customer information for nearly six months without being detected; (2) this subjected Coupang to a materially heightened risk of regulatory and legal scrutiny; (3) When defendants became aware that Coupang had been subjected to this data breach, they did not report it in a current report filing (to be filed with the U.S. Securities and Exchange Commission (the “SEC”)) in compliance with applicable reporting rules; and (4) as a result, defendants’ public statements were materially false and/or misleading at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Coupang class action, go to https://rosenlegal.com/submit-form/?case_id=8383 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© icholakov / Getty Images

Defense contracts have risen sharply in recent years as global security challenges intensify. The ongoing war in Ukraine and escalating tensions in the Middle East have prompted European nations and other allies to replenish depleted munitions and expand their military capabilities. NATO members have committed to higher spending targets, with many countries boosting budgets to address immediate threats and long-term deterrence needs.

In the U.S., the War Department is focusing on replenishing stockpiles drawn down by support for Ukraine while maintaining readiness against potential adversaries. This environment of elevated government spending has created strong demand for advanced defense systems, especially this past year.  

Following President Trump’s election in 2024, he implemented broader budget cuts in some areas, but defense budgets rose as the administration focused on global security challenges and modernizing military capabilities. In particular, spending on advanced technologies, such as artificial intelligence, cybersecurity, and autonomous systems, was prioritized. With the National Defense Authorization Act (NDAA) just signed into law, over $900 billion in funding was authorized, signaling a deliberate push to accelerate delivery on capabilities.

Among the contractors positioned to benefit from this influx of government spending, both at home and abroad, two stand out for their growth potential heading into 2026: RTX (NYSE:RTX) and Kratos Defense & Security Solutions (NASDAQ:KTOS).

RTX (RTX)
RTX has seen its stock climb 60% through 2025, reaching all-time highs near $185 per share as defense orders surged. The company’s Raytheon segment reported a book-to-bill ratio of 2.27 in the third quarter, meaning new orders were double shipments, reflecting robust demand for missile systems amid a global rearmament.

Key contracts highlight this momentum: Just this month, Raytheon secured a $1.7 billion deal to supply Spain with four Patriot fire units — the largest such order for that country — while other awards included sustainment support for Patriot systems and contributions to programs like NASAMS for allies. RTX’s overall backlog hit a record $251 billion in Q3, providing multi-year revenue visibility for the second-largest defense contractor.

As a result of the sustained order flow, RTX raised its full-year 2025 guidance multiple times, citing 12% sales growth this past quarter and strong performance in defense segments. In particular, the replenishment needs in Europe and the U.S. helped organic growth in missiles and integrated defense systems. 

However, RTX also offers diversification because it also services the commercial aerospace industry through its Collins Aerospace and Pratt & Whitney segments. With delays in plane shipment by Boeing (NYSE:BA) and Airbus, older aircraft are flying longer, requiring increased demand for maintenance, repair, and operations solutions. Pratt & Whitney saw a 23% surge in the commercial aftermarket business while Collins saw a 13% rise.

Analysts project continued strength into 2026, with consensus price targets around $196 per share, with high-end targets reaching $219 per share. These imply 6% to 18% upside, but are supported by the ongoing cycle of elevated defense budgets.

Kratos Defense & Security Solutions (KTOS)
Kratos Defense & Security Solutions was one of the industry’s best performers in 2025, with shares soaring 196%, fueled by its focus on affordable unmanned aerial systems and hypersonics. The company’s unmanned segment posted 35.8% revenue growth in the third quarter, with operating income up 575% due to improved scale.

Kratos holds a leading position in tactical drones like the XQ-58A Valkyrie, which offers high performance at lower costs than traditional platforms. In early 2025, it received a $34.8 million contract modification from the U.S. Marine Corps for Valkyrie mission systems integration under the MUX TACAIR program. Additional developments include a letter of intent for 60 Zeus hypersonic motors and partnerships, such as with Airbus for uncrewed combat aircraft variants targeted for delivery by 2029.

Analysts highlight Kratos as a beneficiary of shifts toward collaborative combat aircraft, hypersonics, and counter-drone technologies. KeyBanc analysts named it a top aerospace and defense pick for 2026, citing its first-to-market advantages and leverage to modernization programs. Price targets have also risen, with consensus targets reaching $100 per share, implying 28% upside, but going as high as $125 per share, for 60% upside. These targets reflect expectations for sustained contract wins in unmanned systems, making its stock a buy in 2026.

Expense-conscious investors face a tradeoff between higher yield and long-term resilience when choosing between these two bond ETFs.

The State Street SPDR Portfolio Long Term Corporate Bond ETF (SPLB 0.09%) stands out for its ultra-low fees and higher yield, while the iShares iBoxx Investment Grade Corporate Bond ETF (LQD 0.01%) is larger and has held up better during tough bond markets.

Both SPLB and LQD target U.S. investment-grade corporate bonds, making them core options for fixed income exposure. The main difference: SPLB zeroes in on long-term maturities (10 years or longer), while LQD covers the full investment-grade maturity spectrum.

Snapshot (cost & size)MetricLQDSPLBIssueriSharesSPDRExpense ratio0.14%0.04%1-yr return (as of Dec. 16, 2025)6.2%4.35%Dividend yield4.34%5.2%Beta1.42.1AUM$33.17 billion$1.1 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year weekly returns. The 1-yr return represents total return over the trailing 12 months.

SPLB looks more affordable with a 0.04% expense ratio, undercutting LQD’s 0.14% fee, and it also delivers a higher yield, which may appeal to income-focused investors seeking a bigger payout from their bond allocation.

Performance & risk comparisonMetricLQDSPLBMax drawdown (5 y)(14.7%)(23.31%)Growth of $1,000 over 5 years$801.52$686.55

NYSEMKT: SPLBSPDR Series Trust - State Street SPDR Portfolio Long Termorate Bond ETF

Today's Change

(

-0.09

%) $

-0.02

Current Price

$

22.72

What's insideSPLB tracks investment-grade, U.S. corporate bonds with maturities of 10 years or more, resulting in a portfolio of 2,953 holdings and a fund life of 16.8 years. Its top positions include Meta Platforms (META 0.56%) Sr Unsecured 11/65 5.75 0.39%, Anheuser Busch InBev (BUD +0.64%) Company Guar 02/46 4.9 0.38%, and CVS Health (CVS +0.62%) Sr Unsecured 03/48 5.05 0.33%. The fund’s long duration makes it more sensitive to interest rate movements, which helps explain its higher yield, but also its deeper drawdown in recent years.

LQD also holds only investment-grade corporate bonds but spans all maturities, with 3,002 holdings. Its largest positions are BlackRock (BLK 0.01%) Cash Fund Treasury SL Agency 0.90%, Anheuser Busch InBev 0.23%, and CVS Health 0.20%. This broader approach has helped LQD weather recent volatility better than SPLB, particularly during periods of rising rates.

For more guidance on ETF investing, check out the full guide at this link.

NYSEMKT: LQDiShares Trust - iShares iBoxx $ Investment Grade Corporate Bond ETF

Today's Change

(

-0.01

%) $

-0.01

Current Price

$

110.64

What this means for investorsCorporate bonds are debt securities that companies sell in exchange for cash, basically a sort of IOU. In exchange, investors get interest payments and the face value of the bonds when the bond term ends, known as maturity. Generally speaking, bonds can be strong investments for investors looking for predictable income and portfolio diversification, and corporate bonds can carry higher yields than government bonds, making them more attractive candidates within the asset class.

The LQD and SPLB ETFs, which hold large portfolios of corporate bonds and sell them as a package to retail investors, are pretty similar when it comes to the number of holdings and some of their top positions. One major difference between the two funds is that LQD doesn't limit its holdings by maturity. In fact, 22.3% of its holdings have maturities between three and five years, and 16.6% are between five and seven years. SPLB eliminates these bonds, holding only bonds with maturities of 10 years or more.

LQD's broader range is likely the reason for its slightly better long-term performance and lower beta, which indicates less market volatility. On the other hand, SPLB offers a much lower expense ratio as well as a higher dividend yield.

GlossaryExpense ratio: The annual fee charged by a fund, expressed as a percentage of assets, to cover operating costs.
Dividend yield: The annual income from dividends as a percentage of the fund's price.
Investment-grade: Bonds rated as relatively low risk of default by major credit rating agencies.
Corporate bond: A debt security issued by a corporation to raise capital, paying interest to investors.
Maturity: The date when a bond's principal is repaid to investors and interest payments stop.
Drawdown: The decline from a fund's peak value to its lowest point over a specific period.
Total return: The investment's price change plus all dividends and distributions, assuming those payouts are reinvested.
Beta: A measure of a fund's volatility compared to the overall market, often the S&P 500.
AUM (Assets Under Management): The total market value of assets managed by a fund.
Duration: A measure of a bond's sensitivity to interest rate changes; longer duration means higher sensitivity.
Holdings: The individual securities or assets owned by a fund.

Discover whether Plug Power's turnaround story is finally gaining momentum or if the risks still overshadow the opportunity.

Plug Power (PLUG 1.43%) is navigating a high-stakes transition as demand for electrolyzers grows, new hydrogen plants come online, and major partnerships expand. If the company can stabilize cash burn and improve execution, PLUG could unlock meaningful upside for investors watching the clean energy shift.

Stock prices used were the market prices of Dec. 15, 2025. The video was published on Dec. 24, 2025.

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

TSMC , the world's largest contract chipmaker, said on Saturday that a small number of its facilities in the Hsinchu science park, where it is headquartered, reached evacuation criteria following an earthquake.

A lost source of revenue is likely to reopen once again for the chip giant in the new year.

Nvidia's (NVDA +1.09%) gains on the stock market this year may not have been as great as in 2023 and 2024. However, the semiconductor bellwether still managed to clock respectable gains of 37% despite being under pressure at certain times owing to various factors.

Nvidia stock outperformed the tech-focused Nasdaq Composite's 21% jump by a nice margin. And now, the chip designer is entering the new year with a potentially solid tailwind on its side. President Donald Trump announced earlier in December that Nvidia will be allowed to sell its advanced H200 data center graphics processing units (GPUs) to approved Chinese customers. It looks like the wheels are already in motion, and Nvidia will soon be able to tap the Chinese market once again, according to an exclusive Reuters report.

Let's take a closer look at this news, and check why it is going to be a big boost for this semiconductor stock in the new year.

Image source: Nvidia.

Nvidia's Chinese revenue inflow could begin from February 2026
Reuters spoke to three people familiar with Nvidia's Chinese plans. The news agency learned that Nvidia informed its Chinese customers that it plans to start shipping the H200 processors before the mid-February Lunar New Year holiday.

The Reuters report claims Nvidia will initially ship between 40,000 and 80,000 H200 chips. Nvidia will fulfill these shipments from its existing H200 stock. Given that each H200 processor is priced at around $32,000, Nvidia could sell $1.28 billion to $2.56 billion worth of these chips into the Chinese market in the first quarter of fiscal 2027, which begins at the end of January 2026.

Of course, Nvidia's agreement with the Trump administration is that it will hand over a quarter of its Chinese revenue to the U.S. government. However, it is still a start, nonetheless, for a company that was frozen out of this market in April 2025 following export controls restricting sales of its advanced AI chips to Chinese customers. More importantly, the third source cited by Reuters in its report stated that Nvidia will bring additional production capacity online for its Chinese customers.

The company will start taking orders for the newly added capacity in the second quarter of 2026. This suggests Nvidia is confident regarding the demand for the H200 processors in China. That isn't surprising, as the H200 is around six times more powerful compared to the China-specific H20 processor it was selling there earlier. So, it is easy to see why Chinese tech giants Alibaba, ByteDance, and Tencent are looking to get their hands on these chips.

Another point of note is that Chinese government officials may mandate companies to purchase homegrown chips, along with the H200, to support the growth of local technology. This could further reduce the friction for Nvidia to sell its advanced chips in China, a market where it was on track to sell $30 billion worth of AI chips in the current fiscal year before the restrictions kicked in.

Today's Change

(

1.09

%) $

2.05

Current Price

$

190.66

The stock's returns next year could be better than in 2025
Nvidia already has a significant backlog of data center chip orders to fulfill in 2026, standing at around $275 billion. That number is now likely to head higher following the reopening of its access to the Chinese market, which could pave the way for a stronger jump in its revenue and earnings.

Nvidia has a 12-month median price target of $250, per 69 analysts covering the stock. That suggests a potential jump of 36% from current levels, almost in line with the stock's appreciation this year. However, the recent developments have led analysts to boost their earnings expectations from Nvidia in 2026.

Data by YCharts.

The current $7.52 earnings per share estimate for next year points toward a potential 60% increase from the ongoing fiscal year's estimated earnings of $4.69 per share. However, those estimates can increase once the additional business that Nvidia is likely to receive from China is factored in, paving the way for a bigger jump in this AI stock in 2026 compared to what it delivered this year.

This attractively valued AI software stock could become a multibagger thanks to its healthy position in a fast-growing end market.

Palantir Technologies (PLTR 2.81%) is likely one of the first names that comes to mind when investors are looking for a company that's capitalizing on the proliferation of artificial intelligence (AI). The company's expertise in the generative AI software market is a big reason why that's likely to be the case. After all, Palantir's Artificial Intelligence Platform (AIP) has been a massive hit among customers looking to integrate generative AI technology into their operations, helping them achieve significant productivity gains.

Unsurprisingly, Palantir's growth has accelerated remarkably this year, leading to a 156% surge in its stock price. However, concerns about Palantir's expensive valuation have weighed on the stock of late. This is evident from a 6% increase in its stock price over the past three months, despite the company delivering a solid set of results just last month.

However, shares of Twilio (TWLO +0.11%) have surged in the past three months. The stock has appreciated an impressive 36% during this period, significantly outpacing Palantir's gains. Let's examine why that has been the case and why it may be a good idea to buy this stock right away.

Image source: Getty Images.

AI is boosting Twilio's growth
Twilio is a cloud communications specialist that offers application programming interfaces (APIs), allowing its clients to communicate with their customers across various channels, including text, email, voice, chat, and others. The company's solutions have helped replace traditional contact centers. Its clients simply need the internet and a computer or smartphone to get in touch with their customers, rather than setting up physical contact centers that are more costly to establish and maintain.

Today's Change

(

0.11

%) $

0.15

Current Price

$

140.46

Apart from APIs, Twilio's cloud platform also offers AI-driven insights to its clients. For instance, Twilio customers can improve engagement and drive stronger sales with the help of AI-driven predictive analytics and recommendations. The company enables its clients to make personalized large language models (LLMs) based on customer data to gain a better understanding of customer habits and deploy marketing campaigns accordingly.

Importantly, Twilio's customer base is growing at a faster pace thanks to the adoption of its AI offerings. The company's active customer accounts increased by 22% year over year in the third quarter to 392,000. That was much better than the 4% increase in its active customer accounts in the same quarter last year.

An improvement in the spending of existing customers also accompanies this healthy increase in Twilio's active customer base. The company reported an increase of 4 percentage points in its dollar-based net expansion rate in Q3 to 109%. This metric compares the spending by Twilio's customers at the end of a quarter to the spending by that same customer cohort in the year-ago period. A reading of more than 100% means that existing customers purchased more of Twilio's offerings, and the good part is that this metric expanded at a healthy pace.

Twilio believes it can continue to win a bigger share of its customers' wallets through the cross-selling opportunities that its AI products are creating. Management remarked on the October earnings call that the number of customers using multiple products crossed 20% thanks to the growing adoption of its agentic AI and conversational AI solutions. So, Twilio still has a lot of room to push more cross-sales, and that should help the company clock robust earnings growth.

It reported a 22.5% year-over-year increase in its earnings in Q3 to $1.25 per share on a 15% year-over-year jump in revenue. Investors will do well to note that Twilio's growth trajectory has improved in recent quarters.

TWLO Revenue (Quarterly) data by YCharts.

The stock can turn out to be a long-term winner
The communications platform-as-a-service (CPaaS) market, which Twilio serves, is forecast to grow at an annual rate of 19% through 2034, according to Precedence Research. The market's revenue is anticipated to increase from $23 billion in 2025 to $108 billion in 2034, with AI playing an important role in fueling this growth.

Twilio is on track to end 2025 with just over $5 billion in revenue, indicating that it has a share of almost 22% in this space. That share could improve in the future as AI drives stronger adoption of Twilio's solutions across its customer base. Even if Twilio manages to increase its market share to 25% by 2034, its top line could reach $27 billion by the end of the forecast period.

Twilio is trading at an attractive 4.5 times sales right now, much lower than Palantir's sales multiple of 126. Assuming Twilio trades at even 5.5 times sales in 2034 (in line with the Nasdaq Composite index's sales multiple), its market cap could jump to $148 billion. Twilio currently has a market cap of $22 billion, indicating that this stock has the potential to become a multibagger pick in the long run.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Integer Holdings Corporation (NYSE: ITGR) between July 25, 2024 and October 22, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 9, 2026.

So what: If you purchased Integer common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Integer class action, go to https://rosenlegal.com/submit-form/?case_id=49170 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 9, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Integer materially overstated its competitive position within the growing electrophysiology ("EP") manufacturing market; (2) despite Integer's claims of strong visibility into customer demand, Integer was experiencing a sustained deterioration in sales relating to two of its EP devices; (3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for its cardio and vascular ("C&V") segment; (4) as a result of the above, defendants' positive statements about Integer's business, and operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Integer class action, go to https://rosenlegal.com/submit-form/?case_id=49170 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of OZKAP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I have written put options on OZK's common shares and will continue to do so in an attempt to establish a long position.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Bank of America is too large to fail and can gain market share anytime a banking crises impact regional banks. The consumer banking and investment services are still growing and offer multiple pathways to higher profits.

Lead Plaintiff Deadline is February 6, 2026

, /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Gauzy Ltd. (NASDAQ: GAUZ) ("Gauzy") that a federal securities class action has been filed on behalf of investors who purchased Gauzy between March 11, 2025 through November 13, 2025, inclusive (the "Class Period"). Investors have until February 6, 2026 to seek appointment as lead plaintiff.

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

Allegations

The complaint alleges that Gauzy and certain officers made materially false and misleading statements and/or failed to disclose that:

Three French subsidiaries lacked sufficient financial resources to meet their obligations as they came due;
As a result, it was substantially likely that French insolvency proceedings would be initiated; and
Those proceedings were substantially likely to trigger a default under Gauzy's senior secured debt facilities.

Corrective Disclosures

On November 14, 2025, Gauzy disclosed that the Commercial Court of Lyon ordered the commencement of French insolvency proceedings ("Redressement Judiciaire") for three French subsidiaries. The company further disclosed that these proceedings constituted a default under its existing senior secured debt facilities and that it would delay the release of its Third Quarter 2025 financial results.

Market Reaction

Following these disclosures, Gauzy's stock price declined approximately $2.00 per share, or 49.8%, over two trading days, closing at $2.02 on November 17, 2025.

Investor Deadlines

Lead Plaintiff Deadline: Investors have until FEBRUARY 6, 2026 to contact the firm to discuss how to become a lead plaintiff.

Why Wolf Haldenstein Adler Freeman & Herz LLP?:

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

Contact:

Phone: (800) 575-0735 or (212) 545-4774
Email: [email protected]
Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP

Lead Plaintiff Deadline is February 17, 2026

, /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers Charming Medical Ltd. (NASDAQ: MCTA) ("Charming") that a federal securities class action has been filed on behalf of investors who purchased Integer between October 21, 2025 and November 12, 2025, inclusive (the "Class Period"). Investors have until February 17, 2026 to seek appointments as lead plaintiff.

PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

The filed complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. According to the lawsuit, Charming Medical's stock price experienced a rapid and artificial surge following its Initial Public Offering ("IPO") rising from $4.00 per share to a high of $29.36 without any corresponding fundamental company news.

Plaintiffs allege that this price increase was driven by a fraudulent, social-media-based stock promotion scheme. Investigations and public reporting revealed that impersonators posing as financial advisors promoted Charming Medical through online forums, chat groups, and social media, making sensational and unsupported claims designed to induce retail investor buying.

In November 2025, trading in Charming Medical securities was suspended, allegedly exposing the artificial nature of the run-up and causing investor losses.

The proposed class consists of all persons and entities who purchased Charming Medical securities during the class period and were damaged as a result, excluding defendants and their affiliates.

Lead Plaintiff Deadline: Investors have until FEBRUARY 17, 2026 to contact the firm to discuss how to become a lead plaintiff.

Why Wolf Haldenstein Adler Freeman & Herz LLP?:

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

Contact:

Phone: (800) 575-0735 or (212) 545-4774
Email: [email protected]
Contact Person: Gregory Stone, Director of Case and Financial Analysis

Firm Website: Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP

Also from this source

These profitable businesses have plenty of room left to run.

Growth stocks are a great option for long-term investors due to their potential for high capital appreciation. These companies typically operate in innovative and dynamic industries and reinvest their earnings back into the business to fuel further expansion. This can lead to significant stock price increases through the years that can enrich your portfolio through the beauty of compounding returns.

If you're looking for top growth stocks to buy right now, here are three no-brainer names to consider.

Image source: Getty Images.

1. MercadoLibre
MercadoLibre (MELI +0.50%) is quickly becoming the digital backbone of Latin America, as its integrated e-commerce, logistics, and fintech ecosystem continues to thrive. By handling 95% of its own deliveries through its Mercado Envíos network, MercadoLibre achieves faster and more reliable shipping than its competitors, which remains a critical advantage amid the region's often-challenging infrastructure.

The company's Mercado Pago division provides essential financial services in an underbanked region. Its total credit portfolio has reached $11 billion as of the end of the third quarter of 2025, up 83% from a year ago, and a large portion of its payment volume is coming from outside the e-commerce platform.

MercadoLibre has been cash-flow positive every year since 2007 and has demonstrated an ability to fund its own expansion without excessive reliance on external capital. Newer ventures like digital advertising are high-margin businesses that can leverage the company's vast user data to drive growth and improve overall profitability in the years ahead.

Today's Change

(

0.50

%) $

10.06

Current Price

$

2008.27

In Q3 2025, MercadoLibre's net revenue popped 39% year over year to $7.4 billion, the 27th consecutive quarter of year-over-year growth greater than 30%. Brazil is immensely important to MercadoLibre as the company's single largest and most crucial market, which accounts for over half of its total revenues. Management has emphasized a focus on long-term value creation over short-term margin improvements, making significant investments in logistics and expanding free shipping in Brazil.

The lowered free shipping threshold in Brazil led to a surge in items sold in Q3 (up 42% year over year in Brazil) and the largest quarterly addition of unique buyers in the company's history. Unique buyers in Brazil were up 29% year over year in Q3. MercadoLibre delivered about $718 million in adjusted free cash flow in the first nine months of 2025 alone. If you want to invest in a top-notch e-commerce and fintech stock, MercadoLibre looks like a no-brainer buy.

2. Eli Lilly
Eli Lilly (LLY +0.07%) briefly reached a $1 trillion market cap earlier this year, becoming the first healthcare company to achieve that milestone thanks to the explosive growth and global adoption of its obesity and diabetes treatments. In Q3 2025, Lilly reported 54% year-over-year revenue growth to $17.6 billion. Combined sales of its GLP-1 products Mounjaro (diabetes) and Zepbound (obesity) totaled over $10 billion in a single quarter and now account for more than 50% of the company's total revenue.

Lilly has unseated its rival Novo Nordisk as the market leader in the GLP-1 space and now controls nearly 60% of total U.S. prescriptions for these medications. The company recently submitted a New Drug Application to the FDA for its once-daily GLP-1 pill, forglipron, for the treatment of obesity in adults, following positive results from its Phase 3 trial. In this trial, orforglipron significantly outperformed the placebo in maintaining weight loss over 52 weeks in patients previously on semaglutide (the active ingredient in Ozempic and Wegovy) or tirzepatide (the active ingredient in Mounjaro and Zepbound).

This trial specifically tested weight maintenance after initial intensive treatment to demonstrate orforglipron's role in preventing weight regain. Patients switching from Wegovy regained approximately 2 pounds, and those switching from Zepbound regained approximately 11 pounds compared to the placebo. The pill was awarded a Commissioner's National Priority Voucher.

Today's Change

(

0.07

%) $

0.77

Current Price

$

1077.75

While standard reviews typically take around 10 months, this voucher could result in an FDA decision as early as the first quarter of 2026. Lilly's CEO previously estimated a target approval date around March 2026. A separate application for orforglipron to treat Type 2 diabetes is expected to follow in the new year too. If approved, orforglipron will be the first small-molecule, once-daily oral GLP-1 receptor agonist available for weight management. Analysts expect it to generate up to $40 billion in annual revenue at its peak.

Another key GLP-1 drug candidate is Eli Lilly's retatrutide, a first-in-class triple hormone receptor agonist, which means it mimics the effects of three naturally occurring hunger-regulating hormones simultaneously. The drug is currently in Phase 3 trials and has shown unprecedented weight loss results (averaging 28.2%) in clinical data released in late 2025. Beyond weight loss, Lilly is seeing strong demand for Kisunla, its Alzheimer's treatment, which is expected to launch in multiple European markets in 2026. This appears to be a fantastic healthcare stock to buy and hold for the long term. It also happens to be a long-standing dividend payer, with a yield just under 1% partly due to the stock's generous run-up of 40% over the last year.

3. Alphabet
In Q3 2025, Alphabet (GOOGL 0.20%) (GOOG 0.24%) reported its first-ever $100 billion quarter. Its total revenue reached $102.3 billion (up 16% from a year ago), and diluted earnings per share (EPS) jumped 35.4% to $2.87. The company maintains one of the world's strongest balance sheets, with $98.5 billion in cash and marketable securities as of the last count. Google Cloud revenue increased 34% year over year to $15.2 billion in Q3 2025. Operating margins for this segment also expanded significantly to 23.7%, up from 17.1% a year earlier.

The company has a massive $155 billion backlog of non-recognized sales contracts, which reflects the impressive future demand for its artificial intelligence (AI)-powered infrastructure. Alphabet's primary AI model, Gemini, now has over 650 million monthly active users and is driving a 3x increase in search queries through AI Overviews. Moreover, Alphabet's custom Tensor Processing Units (TPUs) are seeing high demand from external companies, which could potentially create a multibillion-dollar revenue stream.

Despite fears of AI disruption, Google Search revenue grew 14.5% year over year in Q3 to $56.6 billion as the company maintains its roughly 90% global share of the search engine market. Advertising revenue on YouTube grew 15% to $10.3 billion, bolstered by the monetization of Shorts, and paid subscriptions (YouTube Premium, Google One) crossed 300 million, underscoring the ability of this segment to provide a stable, high-margin recurring revenue stream.

Today's Change

(

-0.20

%) $

-0.62

Current Price

$

313.47

Alphabet has been one of the best-performing stocks in the Magnificent Seven for 2025, with shares rising roughly 60% year to date. Despite the rally, it trades at a forward price-to-earnings ratio (P/E) around 28, which is quite reasonable given its more than 30% earnings growth rate. Investors should also pay attention to Alphabet's Waymo. The autonomous driving subsidiary is emerging as a leader in the U.S. robotaxi market, with fully autonomous, publicly available services currently operating in Phoenix, San Francisco, Los Angeles, Atlanta, and Austin, Texas.

Waymo is rapidly expanding, processing over 450,000 paid rides per week, and is reportedly in talks to raise over $15 billion at a valuation approaching $100 billion. Alphabet remains a top tech stock that looks like a great buy now and for the long term if you're a growth-oriented investor seeking a profitable, powerhouse business.

NZAC applies an ESG climate screen and leans more heavily into technology, while URTH follows the traditional developed-markets universe. NZAC charges a lower expense ratio but is much smaller and less liquid than URTH, which may affect trading costs for larger investors.

This stock is a great choice for cautious and aggressive investors.

Investors flocked to Moderna (MRNA 4.73%) stock in the early days of the pandemic for one big reason: The company sold one of the world's most-needed products, a coronavirus vaccine. The vaccine brought in billions of dollars of revenue, and with this first product, Moderna went from a clinical-stage biotech to a highly profitable commercial-stage company in a matter of months.

Though Moderna stock soared back then, in more recent times, the stock has stumbled. The company has seen vaccine sales decline, and its second big product -- its respiratory syncytial virus (RSV) vaccine -- hasn't performed as well as expected when it comes to delivering growth. Still, Moderna has made progress on cost cuts and has refocused its pipeline on several promising programs. And investors may be taking notice. The stock has climbed more than 30% over the past month.

But, if you're looking to invest in a surefire biotech winner, forget Moderna stock. The following player is a much better buy...

Image source: Getty Images.

Why skip Moderna?
So, first, why should you turn away from Moderna right now? The biotech offers a promising recovery story and potentially a long-term growth story too, but it involves some risk: It still must reach certain goals, such as cash breakeven in 2028 or the launch of new products over the next few years. This means Moderna may not be the best choice for cautious investors.

But, Vertex Pharmaceuticals (VRTX 0.01%) is a biotech player that's suitable for both cautious and aggressive investors right now. The company has a long track record of earnings growth thanks to its leadership in cystic fibrosis (CF) treatment -- it's No. 1 worldwide in this area. The company transformed the treatment of this disease with its CFTR modulators, which correct a faulty protein made by the CFTR gene.

Today's Change

(

-0.01

%) $

-0.05

Current Price

$

462.94

Vertex's latest CFTR modulators, Trikafta and Alyftrek, approved in 2019 and in 2024, respectively, treat nearly 95% of those with CF -- and Vertex is working on a candidate to treat this remaining percentage of the CF population that can't be helped by these drugs. Importantly, Vertex's intellectual property protects its position in this market through the late part of the next decade.

Vertex's CF drugs are bringing in billions of dollars in sales -- for example, the company's total revenue climbed 11% to more than $3 billion in the latest quarter -- and this momentum is very likely to continue due to the strength of the CF products.

Winning approval for new products
On top of this, in recent years, Vertex has expanded into other treatment areas and won approval for Casgevy for blood disorders and Journavx for pain management. Both of these could add billions of dollars to Vertex's top line in the coming years. Journavx could become a particularly big product as it fills a major need: Painkillers generally are either over-the-counter options that may not be effective in certain cases or prescription opioids, which have been linked to addiction. Journavx offers doctors and patients an effective, non-opioid option, and so far, they've been receptive. From March, when it became available, through the middle of October, more than 300,000 Journavx prescriptions were filled.

Vertex also has a pipeline including both CF and other candidates that should fuel growth further down the road.

Now, let's take a look at share performance and valuation. Vertex stock has climbed almost 100% over the past five years, and this year it's gained about 15%, showing that it's been a winner in the long term and in the short term. As for valuation, Vertex trades for 25x forward earnings estimates, down from about 27x a few months ago -- today's price may not be dirt cheap, but it's a reasonable price to pay for a company with such leadership in its specialty area and a broadening portfolio of products.

Of course, Vertex may not always be a short-term winner -- like every stock, it might lose momentum at certain points. But this biotech player already has the financial strength and portfolio of products to win over time, and that makes it a better buy right now than Moderna.